Jul. 2 at 7:03 AM
$BFRI I am increasing my position here.
This is not just a random penny name for me. The FDA accepted the Ameluz sNDA for superficial basal cell carcinoma with no filing deficiencies and a PDUFA date set for September 28, 2026.
Q1 also showed real commercial progress:
$10.1M revenue, about 17 percent YoY growth, and gross margin around 80 percent.
Tiny market cap, real FDA catalyst, existing commercial product, and improving fundamentals.
Risk is still there, especially with small cap volatility, but I like the setup into the PDUFA window.
Long and adding carefully. Not financial advice.
